(Press-News.org)
Tuberculosis (TB) is a major unrecognized cause of deadly sepsis among people with HIV in Africa, a sweeping new study reveals. Beginning treatment for TB immediately – even before sepsis patients are diagnosed with TB – could save countless lives, the researchers say.
The ATLAS study, conducted over five years at hospitals in Tanzania and Uganda, has found that more than half of the hundreds of patients enrolled in the study had TB and that immediate treatment increased their chances of survival significantly.
The first-of-its kind study was conducted by researchers at the University of Virginia School of Medicine, Tulane School of Medicine, University of Minnesota and their collaborators in Africa, including leading HIV and tuberculosis physician-scientists Stellah Mpagama from Tanzania’s Kibong’oto Infectious Diseases Hospital and Conrad Muzoora from Uganda’s Mbarara University of Science and Technology.
“In life-threatening sepsis in other parts of the world, a germ causing infection is either not found or is commonly caused by bacteria from urinary tract infections or pneumonia,” said UVA Health researcher Scott Heysell, MD, MPH, who co-led the study. “Instead, we found a treatable form of infection in the majority of people that could be targeted immediately when they presented to care.”
That would enhance the treatment patients receive, improve outcomes and, ultimately, save lives.
“In light of the 30-50% mortality associated with sepsis, our findings suggest that clinicians who work in African settings where HIV and TB are common should probably immediately provide TB treatment to patients who present to hospital with sepsis,” said UVA’s Christopher C. Moore, MD, co-lead investigator. “Given Africa’s disproportionate burden of global sepsis, implementation of this early treatment strategy could result in a substantial reduction in sepsis-related mortality across the region.”
Stopping Deadly Sepsis
Sepsis is dangerous full-body inflammation that can take hold when a person’s immune response spirals out of control in response to an infection, potentially causing organ failure and death. It is the leading cause of death worldwide, and people living with HIV are particularly vulnerable.
The ATLAS study was launched to shed light on the causes of sepsis among people living with HIV in Africa and to find better ways to treat it. After evaluating more than 400 patients with sepsis, the study found that the predominant – and often unrecognized – cause was tuberculosis. More than half of participants in the randomized trial ultimately were found to be suffering from TB.
Further, the researchers found that the highest survival rate was among the patients who received immediate treatment for TB, regardless of whether they had been formally diagnosed. Patients who did not receive TB treatment until their diagnosis had been confirmed, on the other hand, were more likely to die.
This partly reflects the difficulty of confirming a TB diagnosis in Eastern Africa, as the condition can be detectable only with sophisticated blood tests that are often unavailable or delayed, the researchers say. Further, “many of these patients have multiple infections at the same time, which makes their care more challenging,” Mpagama noted.
Current treatment guidelines generally call for TB treatment to be initiated only after a confirmed diagnosis or if the patient has not improved after receiving standard antimicrobial therapy for three to five days. But beginning TB treatment immediately, even without a diagnosis, could save many lives every year, the researchers say.
“This study has the potential to provide a blueprint for evidence-based antimicrobial approach for sepsis therapy in TB-endemic areas,” said Tulane researcher Eva Otoupalova, MD. “My hope is that this work will help lower the extremely high mortality of patients with TB-sepsis.”
Recent funding from the National Institutes of Health is allowing the researchers to continue their work in Uganda and Tanzania. They are launching a new trial to determine whether hydrocortisone to reduce inflammation and/or immediate treatment of TB and other bacterial pathogens will improve survival in patients with HIV-related sepsis.
About the Findings
The researchers have published their findings in a pair of papers in the scientific journals Lancet Infectious Diseases and eClinicalMedicine. The articles are open access, meaning they are free to read.
The ATLAS study was conducted by a team of more than 30 doctors, nurses, pharmacists, study coordinators and statisticians.
The research was funded by NIH grants U01 AI150508, D43 TW012247, R21 AI172637 and K24 AI187675.
To keep up with the latest medical news from UVA and UVA’s new Paul and Diane Manning Institute of Biotechnology, bookmark the Making of Medicine blog at https://makingofmedicine.virginia.edu.
END
New York, Jan. 30, 2026 — More than 4 in 10 women in the U.S. have some form of cardiovascular disease, such as heart disease or stroke — a figure that is only expected to grow. Each year, heart disease and stroke kill more women than all forms of cancer combined.
To help reverse that trend, leading global fashion, beauty and lifestyle retailers joined the American Heart Association volunteers at the New York Stock Exchange to ring the opening bell and sound an alarm — launching the inaugural Go Red. Shop with Heart. campaign to raise funds and awareness of the growing burden of heart disease ...
Korea University College of Medicine (Dean Sung Bom Pyun; Principal Investigator Byung Chul Chun, MD, PhD, MPH) successfully concluded the 2025 Lee Jong-Wook Fellowship on Infectious Disease Specialists Program on October 17. The program is jointly organized by Korea University College of Medicine and GC Labs under the auspices of the Korea Foundation for International Healthcare (KOFIH).
The Lee Jong-Wook Fellowship was established in honor of the late Dr. Jong-Wook Lee, the 6th Director-General of the World Health ...
A new survey shows that there is a clear difference between girls and boys when it comes to well-being at school.
"Girls are happier than boys. This applies both in class and at school in general," says Professor Hermundur Sigmundsson at the Department of Psychology at the Norwegian University of Science and Technology (NTNU).
The researchers questioned 1620 children aged 6 to 9 years in Norway. The average age was 7.5 years old, meaning these were youngest children in primary school.
The gender differences are clear.
Safety ...
UNDER EMBARGO UNTIL 9 am Friday, Jan. 30, 2026
Researchers ...
The globe may be running out of sand suitable for concrete. Researchers are therefore testing a possible solution for using desert sand as a material.
The world's most important building material
Concrete is the world's most widely used building material – second only to water. Globally, more than four billion tonnes of cement are produced every year. Concrete consumption is so enormous that it accounts for around eight percent of the world's CO₂ emissions.
To make concrete, sand is needed, and not just any sand: it must be of the right size and shape. Therefore, rock is crushed into gravel and sand, and river sand is excavated ...
Fukuoka, Japan—University campuses are often places of learning and discovery, but rarely do researchers find a new species living right on their doorstep. However, that is exactly what happened when a research team from Kyushu University discovered a new species of ladybird beetle, Parastethorus pinicola, on a pine tree at Kyushu University’s Hakozaki Satellite.
The discovery, published in Acta Entomologica Musei Nationalis Pragae, was part of a three-year study that revises the classification of the tribe Stethorini —a group of tiny ladybirds known for preying on spider mites—in Japan for the first time ...
PULLMAN, Wash. — The class of anti-inflammatory drugs known as TNF-inhibitors has brought relief to many sufferers of rheumatoid arthritis, but they don't work for up to 4 of every 10 patients.
New research led by Washington State University may have discovered why: a “backdoor” pathway of inflammation that sidesteps medicines that lock the front door.
The findings, published in the journal Cellular & Molecular Immunology, suggest new avenues for improving the treatment of rheumatoid arthritis, a debilitating autoimmune disease where the body attacks its own joints. The disease affects roughly 1% of the world’s population, and the discovery could have positive ...
The precise control of tiny droplets on surfaces is essential for advanced manufacturing, pharmaceuticals, and next-generation lab-on-a-chip diagnostics. However, once droplet volume reaches pico- and nanoliter scales, the droplets become extremely sensitive to microscopic surface irregularities, and friction at the solid–liquid interface becomes a major obstacle to smooth transport.
Against this backdrop, a study led by Dr. Mizuki Tenjimbayashi and his colleagues at Materials Nanoarchitectonics (MANA) proposed a novel strategy that involved coating the droplet with a repellent material instead of engineering a perfectly smooth surface. This study published in the journal ACS Nano has ...
The demand for energy is ever-increasing across various industries. In recent decades, scientists have explored the electrostatic potential of particulate matter as a highly promising avenue for energy harvesting. However, this technology poses ignition risks that can cause significant harm owing to uncontrolled electrical discharge. While some studies have attempted to mitigate this issue by introducing additional particles or water, these approaches lead to restricted applicability and also ignore the high electric potential.
In previous research, a team of researchers from South Korea, including Professor Sangmin Lee from the School ...
A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold standard because it is convenient and familiar. However, for a pill to work, its active ingredients must first dissolve in the fluids of the gastrointestinal tract before they can be absorbed into the bloodstream. If a drug dissolves too slowly or incompletely, its therapeutic effect can be compromised. This so-called ‘solubility crisis’ has become one of the main bottlenecks in modern drug development, affecting as much as 90% of active compounds currently under ...
